CSL Limited posts strong first-half financials

14 February 2023

Australian biotech company CSL Limited (ASX: CSL), the world's No 2 influenza vaccine provider in sales, today released financial results for the fist half of fiscal year 2022/23, showing that total revenues were up 19% to US$7.184 billion, US$889 million of which is attributable to CSL Vifor.

CSL delivered a net profit after tax of $1.62 billion for the first half of financial year 2023, steady at constant currency (CC) . This included one-off costs associated with the acquisition of Vifor Pharma. Underlying profit (NPATA attributable to CSL shareholders) was $1.82 billion, up 10% at CC.

NPATA earnings per share were $3.772. CSL Guidance reaffirmed guidance: FY 2023 NPATA is anticipated to be in the range of approximately $2.7 billion to $2.8 billion at CC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK